We report on a patient with Hodgkin's disease who presented with hypodense splenic lesions and corresponding increased glucose metabolism in FDG-PET imaging, four months after completion of initial treatment, suggestive of early relapse. Serological testing for toxoplasma gondii, however, showed evidence of a recently reactivated or newly acquired infection. Three weeks after immediate antibiotic treatment with Daraprime and Sulfadiazin, the splenic lesions had completely resolved. Additionally, serological titers for toxoplasma gondii were normalized and whole body FDG-PET imaging showed no metabolic activity. Although the positive predictive value of PET imaging to indicate lymphoma is reported to be higher than CT, hypermetabolic lesions are not specific for malignant tissue. Whereas benign tumors typically show low glucose metabolism, activated granulocytes and macrophages may display significantly increased glucose consumption. In conclusion, our case report shows that although therapeutic decisions are often based on the results of imaging modalities, the taking of a detailed history and the acquisition of histological confirmation of the suspected lymphoma relapse are also advisable where possible. Cellular immunodeficiency can result in severe infections even in patients with intermediate stage Hodgkin's lymphoma in remission after combined modality treatment. Therefore, despite the high sensitivity of FDG-PET imaging for the detection of recurrent lymphoma, the differential diagnosis of infectious lesions should be kept in mind, in particular in immunocompromised patients.
Introduction
The staging of patients with Hodgkin's disease is mainly based on physical examination and detection of suspicious masses by CT imaging. A bone marrow biopsy is also considered to be essential. Diffuse infiltration of parenchymatous organs may be missed by CT, so that additional biopsies are recommended if involvement of the liver, spleen or any other organ is suspected. Recently, the imaging metabolic tissue pattern has been shown to improve the diagnostic accuracy when staging malignant diseases [1, 2] . Following malignant transformation, increased glucose metabolism of neoplastic tissue can be visualized by positron emission tomography (PET) using the radiolabeled glucose analogue fluorine-18-fluorodeoxyglucose (FDG). Malignant Lymphoma is characterized by significantly increased glucose consumption of involved tissue. Whole body FDG-PET imaging detects the location and extension of the disease, not only in lymph nodes but also in the spleen, liver and the lungs [3] [4] [5] . Stumpe et al. studied 53 patients with Hodgkin's disease and found a sensitivity of 86% for PET compared to 81% for CT [5] . Moreover, PET imaging provided a specificity of 96% in contrast to 41% for CT. Bangerter et al. found a positive FDG-PET result in 38 (86%) out of 44 newly diagnosed patients with Hodgkin's disease [3] . Compared to findings of conventional staging, PET imaging suggested an up-staging in five patients and down-staging in one patient, resulting in changes in treatment strategy in all six cases (14%). Furthermore, PET detected additional lesions in five cases not identified by conventional staging methods. However, PET failed to visualize sites of Hodgkin's disease in four patients and was false-positive in two patients. Similar results were found in 20 patients at diagnosis of untreated Hodgkin's disease, or at first relapse, resulting in a different clinical staging in 3 patients [4] . Finally, FDG-PET has been reported to successfully identify viable tumor tissue in residual masses following chemo-or radiotherapy [6] [7] [8] . While CT imaging cannot distinguish between residual lymphoma and fibrotic scar tissue, negative FDG-PET imaging is highly predictive of disease-free states. As a result of higher tracer uptake and improved spatial resolution and image quality, positron emission tomography with FDG has replaced Gallium-67 scintigraphy at many institutions where PET is available.
Case report
A 31-year-old female presented with palpable cervical lymph nodes. Lymph node biopsy revealed Hodgkin's Following the HD-11 study protocol of the German Hodgkin's Lymphoma Study Group, the patient was randomized to treatment with four cycles of chemotherapy with ABVD and a 30 Gy involved field radiotherapy. After four cycles of chemotherapy the patient was classified as being in partial remission with a reduction of the mediastinal mass from 11 x 7 cm to 4x2 cm. Remission was consolidated by 30 Gy involved field radiotherapy. Thereafter, the patient still presented with a residual mediastinal mass on CT (Figure lb ) which was demonstrated not to be metabolically active by FDG-PET imaging. Therefore, the patient was classified as being in complete remission. At the follow-up examination two months later, physical examination revealed no evidence of lymphadenopathy or organomegaly. The ESR was 10 mm/hr, the routine blood counts showed 4820 leucocytes/ul with a lymphopenia of 420/ul. Laboratory values were within a normal range. TheT 4 /T 8 ratio was 0.57 with an absolute number of CD4 positive T cells of 83/ul. On CTscan the mediastinal mass was still present with no further decrease in size compared to the staging after completion of therapy. However, a clearly defined hypodense nodular infiltrate was detected in the spleen without any other abnormalities in the abdomen (Figures 2a, b) . In contrast, on ultrasound examination, the spleen was 8 x 4 cm in diameter without evidence of nodular structures. A subsequent FDG-PET scan revealed intensive focal FDG uptake in the spleen.
suggesting recurrence of the disease (Figure 2c ). However, due to high procedure-related risks, such as bleeding and development of a pneumothorax, the patient did not undergo a CT-guided biopsy.
The most probable differential diagnosis of hypodense lesions on CT imaging are splenic abcesses. However, the patient had no fever and no leucocytosis and no other symptoms of a bacterial abscess. Serological testing for Candida albicans and the human immundeficiency virus (HIV) were negative. The patient had not traveled abroad during the previous few months. However, there was a history of being scratched by a cat a few weeks before. Serological testing for toxoplasmosis revealed a Sabin-Feldman titer of 1:1024, toxoplasma-KBR titer of 1 :10 and positive toxoplasma IgM-antibodies with an igM-ISAGA Index of 11, which was a highly significant positive serological reaction. Screening for other signs of infection with toxoplasma gondii revealed a normal cranial MRTand no ocular or myocardial involvement. The patient was immediately treated with Pyrimethamine and Sulfadiazin supported by folinic acid over four weeks. Three weeks after the antibiotic treatment, CT scan and FDG-PET were both normal and the size of the mediastinal mass had further decreased to 3 x 2 cm. Routine blood counts, liver and renal function tests were in the normal range. The absolute count of CD4+ cells (90/ul) was still low. The Sabin-Feldman titer decreased to 1:256, the toxoplasma IgM-ISAGA Index to 6. The patient was in an overall good clinical condition and clinical examinations and CT scans at a six-month followup were normal without any signs of active infection or recurrence of Hodgkin's lymphoma. 
Discussion
We presented a patient with hypodense lesions in the spleen on CT imaging at early follow-up which were metabolically active in PET imaging and turned out to be a rare case of toxoplasmosis. The most important differential diagnosis of hypodense focal splenic lesions in CT scans in patients with Hodgkin's lymphoma is secondary tumor involvement, which is the most common splenic malignancy. Splenic involvement is present at the time of diagnosis in 25%-30% of patients with Hodgkin or non-Hodgkin lymphoma [9] . Splenic involvement may present differently: e.g., homogeneous organ enlargement, miliary nodules, multifocal or as a focal solitary mass. Other differential diagnoses are rare. Since the initial CT was normal in our patient a number of benign lesions, which may also present as hypodense focal areas, were excluded. These comprise haemangioma and lymphangioma, which are the most common benign tumors of the spleen, as well as hamartoma and granulomatous disease such as sarcoidosis [10, 11] . The second most important CT differential diagnosis of focal splenic lesions in immuncompromised patients is splenic infection [12, 13] . Ooi and Leong reviewed 287 cases reported in the literature between 1987 and 1995 and found staphylococcus, salmonella and Escherichia coli to be the most common microorganisms [14] . Rare cases of abscesses with mycobacterium tuberculosis or various fungi have also been reported [13] [14] [15] . Abscesses may appear focal or miliary and focal abscesses often show peripheral contrast enhancement. CT is more sensitive than ultrasound in diagnosing splenic abscesses; a sensitivity of 92.2% is reported for CT compared to 87.2% for ultrasound [14] . However, at an early stage, CT may not demonstrate the presence of splenic abscesses and the use of contrast media may rarely dissimulate infectious foci.
Intracellular accumulation of the radiolabeled glucose analogue F-18-fluorodeoxyglucose does not indicate a tumor specific process. Acute soft tissue infections, abscesses as well as tuberculosis and sarcoidosis, have also been reported as having significant glucose consumption [16, 17] . Therefore, false-positive PET results may occur due to increased glycolysis of activated granulocytes and macrophages. Metabolic characterization of pancreatic masses for example differentiates between pancreatic cancer and chronic pancreatitis but not acute inflammation [18] . The specificity of FDG-PET imaging greatly depends on the prevalence of acute inflammatory processes and ranges from 60% for ovarian masses, to almost 100% for axillary lymph node staging in breast cancer [2] . Increased FDG uptake in benign tumors is rare, however, follicular thyroid nodules, ductal adenoma of the breast and endometriosis have been reported false-positive [2] . False-negative PET results are mainly caused by low metabolic activity of tumor tissue.
To our knowledge, isolated splenic abscesses caused by toxoplasmosis gondii have not been reported so far. However, there are several reports which describe a poor prognosis for untreated toxoplasma infections in immunocompromised patients, especially in patients with Hodgkin's lymphoma [19, 20] . Hodgkin's lymphoma is associated with impaired systemic cellular immunity while immunoglobuline levels and B cell function are often normal [21] . Therefore, these patients are susceptible to infections with viruses, e.g., the varicella-zoster virus and parasites including toxoplasma gondi or pneumocystis carinii, which require a sufficient T-cell response. Besides Hodgkin related death, infectious complications are the second leading cause of morbidity and mortality in patients with Hodgkin's lymphoma.
Regarding the appropriate treatment, histological verification of the hypodense splenic lesions was discussed, however, due to high procedure-related risks, the patient did not undergo a CT guided fine needle biopsy. Therefore, since the combination of patients history, serological testing, severe cellular immunodeficiency and newly diagnosed focal lesions to the spleen was indicative of a toxoplasma gondii infection, immediate antibiotic treatment, with Daraprime and Sulfadiazin for four weeks, was initiated. Three months later the splenic lesions had completely resolved. Additionally serological titers for toxoplasma gondii were normalized and whole body FDG-PET imaging showed no metabolic activity. When the patient presented for follow-up, nine months later, she was in ongoing complete remission. Of note, spleen-preserving management by antibiotic treatment alone may not be possible in all patients and often splenectomy under antibiotic treatment is necessary as a definitive therapy of pyogenic splenic abscesses [13] .
Conclusion
Our case report shows that although therapeutic decisions are often based on the results of imaging modalities, the taking of a detailed history and the acquisition of histological confirmation of the suspected lymphoma relapse are also advisable where possible. Cellular immunodeficiency can result in severe infections even in patients with intermediate stage Hodgkin's lymphoma in remission after combined modality treatment. Therefore, despite the high sensitivity of FDG-PET imaging for the detection of recurrent lymphoma, the differential diagnosis of infectious lesions should be kept in mind, in particular in immunocompromised patients.
